Cargando…

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10(®) to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies

Background. Monitoring of biological TNF inhibitors is a very important tool to guide clinical decisions using specialized algorithms, especially in gastroenterology. A new chemiluminescent instrument (i-TRACK(10®) from Theradiag) could replace ELISA techniques to calculate the dosage of drugs and a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berger, Anne Emmanuelle, Gleizes, Aude, Waeckel, Louis, Roblin, Xavier, Krzysiek, Roman, Hacein-Bey-Abina, Salima, Soriano, Alessandra, Paul, Stephane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455629/ https://www.ncbi.nlm.nih.gov/pubmed/36076966 http://dx.doi.org/10.3390/ijms23179561

Ejemplares similares

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
por: Abbara, Salam, et al.
Publicado: (2019)

Gene therapy for severe combined immunodeficiencies and beyond
por: Fischer, Alain, et al.
Publicado: (2019)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

Low Percentage of Signal Regulatory Protein α/β(+) Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients
por: Magill, Laura, et al.
Publicado: (2018)

A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort
por: Duhazé, Julianne, et al.
Publicado: (2020)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
por: Orts, Beatriz, et al.
Publicado: (2022)

Engineering Next-Generation CAR-T Cells for Better Toxicity Management
por: Andrea, Alain E., et al.
Publicado: (2020)

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
por: Gu, Bonita, et al.
Publicado: (2022)

Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach
por: Duhazé, Julianne, et al.
Publicado: (2020)

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab
por: Gorovits, B., et al.
Publicado: (2018)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
por: Andrea, Alain E., et al.
Publicado: (2022)

DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer
por: Wang, Gary P., et al.
Publicado: (2008)

Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center
por: Tighe, Donal, et al.
Publicado: (2017)

INSPIIRED: Quantification and Visualization Tools for Analyzing Integration Site Distributions
por: Berry, Charles C., et al.
Publicado: (2016)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab
por: Cherry, Mohamad, et al.
Publicado: (2020)

Comparison of a Point-of-Care Analyzer With a Chemiluminescent Immunoassay for Serum Progesterone Measurement in Breeding Management of the Bitch
por: Zuercher, Julia, et al.
Publicado: (2021)

Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease
por: Matei, Diana E., et al.
Publicado: (2021)

Evaluation of a new chemiluminescence immunoassay for diagnosis of syphilis
por: Mo, Xiaohui, et al.
Publicado: (2010)

Chemiluminescence based immunoassay for the detection of heroin and its metabolites
por: Singh, Smritee, et al.
Publicado: (2018)

Chemiluminescence Immunoassay to Detect Anti‐HTLV‐I Antibodies
por: Kamihira, Shimeru, et al.
Publicado: (1993)

Highly Specific Chemiluminescence Immunoassay for the Determination of Chloramphenicol in Cosmetics
por: Li, Qiyan, et al.
Publicado: (2019)

Evaluation of a Chemiluminescent Immunoassay for Measurement of Equine Insulin
por: Carslake, H.B., et al.
Publicado: (2017)

Immunochromatography and chemiluminescent enzyme immunoassay for COVID-19 diagnosis
por: Ishii, Toshiaki, et al.
Publicado: (2021)

Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
por: Kato, Masaichi, et al.
Publicado: (2021)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Chemiluminescent immunoassay technology: what does it change in autoantibody detection?
por: Cinquanta, Luigi, et al.
Publicado: (2017)

An Automated and Highly Sensitive Chemiluminescence Immunoassay for Diagnosing Mushroom Poisoning
por: Zhu, Jianyu, et al.
Publicado: (2021)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
por: Huang, Vivian W., et al.
Publicado: (2015)

Clinical diagnostic performance of light‐initiated chemiluminescent assay compared with the Architect chemiluminescence immunoassay for detection of HCV antibody
por: Yang, Shuo, et al.
Publicado: (2019)

Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo
por: Menegatti, Silvia, et al.
Publicado: (2021)

Different Vancomycin Immunoassays Contribute to the Variability in Vancomycin Trough Measurements in Neonates
por: Samardzic, Janko, et al.
Publicado: (2016)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Adalimumab/infliximab: Lower serologic response: 6 case reports
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b8s39bp4uoi3frff8kdos3i39h